Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

180.35 +2.91 (+1.64%)
Streaming Delayed Price Updated: 3:15 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
80 81 Next >
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)... 
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. 
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere. 
Via Investor's Business Daily
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
Dividend Kings with above-average yields have been badly underperforming the broader markets. 
Via The Motley Fool
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
These are the best blue-chip stocks for investors to consider among a group of already strong equities available in the market. 
Via InvestorPlace
Medtronic Stock: Bull vs. Bear
The medical device maker's shares have gained a little more than 1% so far this year. 
Via The Motley Fool
How Is The Market Feeling About AbbVie?
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal... 
Via Benzinga
These are the top sectors for blue chip growth in 2024
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
AbbVie Unusual Options Activity
Via Benzinga
3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies
If you are an investor looking for secret rising stars, explore these three that can reach trillion dollar status. 
Via InvestorPlace
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Could AbbVie Stock Help You Become a Millionaire?
Buying the stock at a cheap price today could help you achieve some great long-term returns. 
Via The Motley Fool
3 "Boring" Stocks That Could Make You Rich
Boring could be beautiful with these stocks. 
Via The Motley Fool
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Investors have favored an exciting billion-dollar opportunity at Eli Lilly. 
Via The Motley Fool
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
Although you can’t usually have your cake and eat it too, these compelling high-yield dividend growth stocks may prove otherwise. 
Via InvestorPlace
7 High-Yield Blue Chips Suitable for Any Retiree
Here are seven high-yield blue-chip stocks to help you meet your retirement goals no matter where you are on your investment journey. 
Via InvestorPlace
Topics Retirement
Exposures Pension
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
Both companies' share prices have slipped recently. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Dividend Stocks Every Investor Should Own to Survive a Market Crash
When the going gets tough, the tough buy dividend stocks for a market crash because the income they generate softens the downturn's blow. 
Via InvestorPlace
2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade
These stocks could be great investments to bump up your passive income stream. 
Via The Motley Fool
3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing
You'll be happy to own these top companies in any market environment. 
Via The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.